SPHK2 and hepatocellular carcinoma: Liang et al designed Sphk2 siRNA‐loaded nanoparticles to reduce the expression of Sphk2 protein, ultimately leading to the ablation of exosomal miRNA and the inhibition of the tumorigenic potency of TDEs in HCC.